Lateral Sclerosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LTR001 MIFTS: 60	Lateral Sclerosis Categories: Genetic diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lateral Sclerosis

MalaCards integrated aliases for Lateral Sclerosis:

Name: Lateral Sclerosis ¹² ¹⁵ ⁷³

Primary Lateral Sclerosis ¹² ⁷⁶ ⁵³ ⁵⁴ ⁵⁵

Adult-Onset Primary Lateral Sclerosis ¹² ⁵³

Motor Neuron Disease ⁴⁴ ⁷³

Adult-Onset Pls ⁵³

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:230

ICD10 ³³ G12.23

ICD9CM ³⁵ 335.24

MeSH ⁴⁴ D016472

NCIt ⁵⁰ C129933

SNOMED-CT ⁶⁸ 81211007

UMLS ⁷³ C0154682 C0085084

Sources

Summaries for Lateral Sclerosis

NIH Rare Diseases : ⁵³ Primary lateral sclerosis (PLS) is a rare neuromuscular disease that affects the nerve cells that control the voluntary muscles. Problems in the legs (such as weakness, stiffness, spasticity, and balance problems) are often observed first, but hand clumsiness and changes in speech can be early symptoms, as well. The condition is progressive (gradually becomes worse over time); however, affected people have a normal life expectancy. The underlying cause of adult PLS is currently unknown. In most cases, it occurs sporadically in people with no family history of the condition. A subtype of PLS, called juvenile PLS, is caused by changes (mutations) in the ALS2 gene and is inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Lateral Sclerosis, also known as primary lateral sclerosis, is related to amyotrophic lateral sclerosis 2, juvenile and primary lateral sclerosis, adult, 1, and has symptoms including ataxia, myoclonus and hemiplegia. An important gene associated with Lateral Sclerosis is ALS2 (ALS2, Alsin Rho Guanine Nucleotide Exchange Factor), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Riluzole and Mexiletine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : ¹² A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs.

Wikipedia : ⁷⁶ Primary lateral sclerosis (PLS) is a rare neuromuscular disease characterized by progressive muscle... more...

Sources

Related Diseases for Lateral Sclerosis

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile

Primary Lateral Sclerosis, Adult, 1

Diseases related to Lateral Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 386)

#	Related Disease	Score	Top Affiliating Genes
1	amyotrophic lateral sclerosis 2, juvenile	34.4	ALS2 ALS2CR12 SOD1
2	primary lateral sclerosis, adult, 1	34.3	ALS2 SOD1
3	amyotrophic lateral sclerosis 4, juvenile	34.3	ALS2 SETX
4	amyotrophic lateral sclerosis type 6	34.3	ALS2 FUS SETX TARDBP
5	amyotrophic lateral sclerosis 16, juvenile	34.2	ALS2 SIGMAR1 SOD1
6	frontotemporal dementia and/or amyotrophic lateral sclerosis 1	34.2	C9orf72 CHCHD10 FUS TARDBP UBQLN2 VCP
7	amyotrophic lateral sclerosis 18	34.1	C9orf72 FUS SOD1 TARDBP
8	juvenile amyotrophic lateral sclerosis	34.1	ALS2 FUS SETX SIGMAR1
9	amyotrophic lateral sclerosis 20	34.0	ALS2 HNRNPA1
10	amyotrophic lateral sclerosis 10 with or without frontotemporal dementia	34.0	ALS2 ANG FIG4 FUS SETX TARDBP
11	amyotrophic lateral sclerosis 11	34.0	ALS2 ANG FIG4 FUS SETX TARDBP
12	amyotrophic lateral sclerosis 9	34.0	ALS2 ANG FIG4 FUS SETX TARDBP
13	amyotrophic lateral sclerosis 21	33.9	C9orf72 FUS SETX SOD1 TARDBP VAPB
14	amyotrophic lateral sclerosis 7	33.9	ALS2 ANG FIG4 FUS SETX TARDBP
15	amyotrophic lateral sclerosis type 14	33.9	FUS TARDBP UBQLN2 VAPB VCP
16	frontotemporal dementia	32.9	C9orf72 CHCHD10 FUS HNRNPA1 NEFH SOD1
17	amyotrophic lateral sclerosis 1	32.6	ALS2 ANG C9orf72 CHCHD10 DCTN1 FIG4
18	progressive muscular atrophy	32.4	C9orf72 TARDBP
19	motor neuron disease	31.9	ALS2 C9orf72 CHCHD10 DCTN1 FUS NEFH
20	distal hereditary motor neuropathies	31.8	DCTN1 SETX
21	perry syndrome	31.7	C9orf72 DCTN1 TARDBP
22	nervous system disease	31.6	C9orf72 SOD1 TARDBP
23	dementia	30.8	C9orf72 CHCHD10 FUS HNRNPA1 TARDBP TRPM7
24	spinal muscular atrophy	30.6	CHCHD10 HNRNPA1 SIGMAR1 VAPB
25	progressive non-fluent aphasia	30.1	C9orf72 VCP
26	brown-vialetto-van laere syndrome	30.1	ALS2 C9orf72 SOD1 TARDBP UBQLN2
27	charcot-marie-tooth disease	30.0	DCTN1 FIG4 NEFH SETX VCP
28	behavioral variant of frontotemporal dementia	29.9	C9orf72 VCP
29	postpoliomyelitis syndrome	29.9	TARDBP VCP
30	semantic dementia	29.8	C9orf72 TARDBP
31	primary lateral sclerosis, juvenile	12.7
32	madras motor neuron disease	12.7
33	amyotrophic lateral sclerosis-parkinsonism/dementia complex 1	12.7
34	amyotrophic lateral sclerosis 8	12.7
35	amyotrophic lateral sclerosis 19	12.6
36	amyotrophic lateral sclerosis 6 with or without frontotemporal dementia	12.5
37	amyotrophic lateral sclerosis 17	12.5
38	amyotrophic lateral sclerosis 12	12.5
39	amyotrophic lateral sclerosis 14 with or without frontotemporal dementia	12.5
40	frontotemporal dementia and/or amyotrophic lateral sclerosis 2	12.5
41	frontotemporal dementia and/or amyotrophic lateral sclerosis 3	12.5
42	frontotemporal dementia and/or amyotrophic lateral sclerosis 4	12.5
43	amyotrophic lateral sclerosis 23	12.5
44	amyotrophic lateral sclerosis 15 with or without frontotemporal dementia	12.5
45	amyotrophic lateral sclerosis 3	12.5
46	amyotrophic lateral sclerosis type 5	12.5
47	amyotrophic lateral sclerosis 25	12.5
48	amyotrophic lateral sclerosis 22 with or without frontotemporal dementia	12.5
49	amyotrophic lateral sclerosis 24	12.5
50	amyotrophic lateral sclerosis 5, juvenile	12.4

Graphical network of the top 20 diseases related to Lateral Sclerosis:

Sources

Symptoms & Phenotypes for Lateral Sclerosis

UMLS symptoms related to Lateral Sclerosis:

ataxia, myoclonus, hemiplegia, muscular fasciculation

GenomeRNAi Phenotypes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

²⁶ (show all 11)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00106-A-0	10.39	DCTN1
2	Decreased viability	GR00221-A-1	10.39	TRPM7
3	Decreased viability	GR00221-A-2	10.39	SOD1 TRPM7
4	Decreased viability	GR00221-A-3	10.39	SOD1
5	Decreased viability	GR00221-A-4	10.39	FUS SOD1 TRPM7
6	Decreased viability	GR00342-S-2	10.39	TRPM7
7	Decreased viability	GR00381-A-1	10.39	ANG FIG4 SIGMAR1 VCP
8	Decreased viability	GR00381-A-3	10.39	SIGMAR1
9	Decreased viability	GR00402-S-2	10.39	ALS2 ALS2CR12 ANG C9orf72 CHCHD10 DCTN1
10	no effect	GR00402-S-1	9.96	ALS2 ALS2CR12 ANG C9orf72 CHCHD10 DCTN1
11	shRNA abundance <= 50%	GR00343-S	9.32	ANG FUS HNRNPA1 RNF19A SETX SOD1

MGI Mouse Phenotypes related to Lateral Sclerosis:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.03	ALS2 C9orf72 DCTN1 FIG4 NEFH RNF19A
2	cellular	MP:0005384	9.9	C9orf72 CHCHD10 DCTN1 NEFH RNF19A SETX
3	muscle	MP:0005369	9.5	ALS2 DCTN1 FIG4 SOD1 TARDBP VAPB
4	nervous system	MP:0003631	9.4	ALS2 C9orf72 DCTN1 FIG4 NEFH PRPH

Sources

Drugs & Therapeutics for Lateral Sclerosis

Drugs for Lateral Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Riluzole

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

1744-22-5

5070

Mexiletine

Approved, Investigational

Phase 4,Phase 2

31828-71-4

4178

Armodafinil

Approved, Investigational

Phase 4

112111-43-0

Modafinil

Approved, Investigational

Phase 4

68693-11-8

4236

Neurotransmitter Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Excitatory Amino Acid Antagonists

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Protective Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Anticonvulsants

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Excitatory Amino Acids

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Neuroprotective Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Anti-Arrhythmia Agents

Phase 4,Phase 3,Phase 2

Diuretics, Potassium Sparing

Phase 4,Phase 3,Phase 2,Phase 1

Sodium Channel Blockers

Phase 4,Phase 3,Phase 2,Phase 1

Cytochrome P-450 CYP3A Inducers

Phase 4

Central Nervous System Stimulants

Phase 4,Phase 1

Wakefulness-Promoting Agents

Phase 4

Olanzapine

Approved, Investigational

Phase 2, Phase 3

132539-06-1

4585

Iron

Approved

Phase 2, Phase 3,Not Applicable

7439-89-6

23925

Lithium carbonate

Approved

Phase 2, Phase 3

554-13-2

Methylcobalamin

Approved, Experimental, Investigational

Phase 2, Phase 3,Phase 3

13422-55-4

Dopamine

Approved

Phase 2, Phase 3,Phase 3,Phase 1

51-61-6, 62-31-7

681

Memantine

Approved, Investigational

Phase 2, Phase 3

19982-08-2

4054

Antipyrine

Approved, Investigational

Phase 3,Phase 1,Phase 2

60-80-0

2206

Hydroxocobalamin

Approved

Phase 2, Phase 3,Phase 3

13422-51-0

11953898 44475014

Zinc

Approved, Investigational

Phase 3,Phase 1,Phase 2

7440-66-6

Mecasermin

Approved, Investigational

Phase 3

68562-41-4

Lenograstim

Approved, Investigational

Phase 2, Phase 3,Not Applicable

135968-09-1

Pramipexole

Approved, Investigational

Phase 3,Phase 1,Phase 2

104632-26-0

119570 59868

Minocycline

Approved, Investigational

Phase 3,Phase 2

10118-90-8

5281021

Tocopherol

Approved, Investigational

Phase 3

1406-66-2

14986

Valproic Acid

Approved, Investigational

Phase 3,Phase 2

99-66-1

3121

Ceftriaxone

Approved

Phase 3

73384-59-5

5479530 5361919

Acetylcholine

Approved

Phase 2, Phase 3,Phase 3,Not Applicable

51-84-3

187

Quinidine

Approved, Investigational

Phase 3,Phase 2

56-54-2

441074

Dextromethorphan

Approved

Phase 3,Phase 2

125-71-3

5360696 5362449

Guaifenesin

Approved, Investigational, Vet_approved

Phase 3,Phase 2

93-14-1

3516

Citalopram

Approved

Phase 3

59729-33-8

2771

Deferiprone

Approved

Phase 2, Phase 3,Not Applicable

30652-11-0

2972

Creatine

Approved, Investigational, Nutraceutical

Phase 3,Phase 2

57-00-1

586

Cyanocobalamin

Approved, Nutraceutical

Phase 2, Phase 3,Phase 3

68-19-9

44176380

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3,Phase 3,Phase 1

59-30-3

6037

Vitamin E

Approved, Nutraceutical, Vet_approved

Phase 3

59-02-9

14985

Coenzyme Q10

Approved, Investigational, Nutraceutical

Phase 3,Phase 2

303-98-0

5281915

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2

77-92-9

311

Cobalamin

Experimental

Phase 2, Phase 3,Phase 3

13408-78-1

6438156

Tocotrienol

Investigational

Phase 3

6829-55-6

Simendan

Investigational

Phase 3,Phase 2

131741-08-7

Antiemetics

Phase 2, Phase 3

Antipsychotic Agents

Phase 2, Phase 3,Phase 3

Psychotropic Drugs

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 503)

#	Name	Status	NCT ID	Phase	Drugs
1	Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis	Unknown status	NCT00560287	Phase 4
2	CARE Canadian ALS Riluzole Evaluation	Completed	NCT00542412	Phase 4	Riluzole
3	Mexiletine for the Treatment of Muscle Cramps in ALS	Completed	NCT01811355	Phase 4	Mexiletine;Placebo
4	Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)	Completed	NCT00613899	Phase 4
5	Modafinil for Treatment of Fatigue in ALS Patients	Completed	NCT00614926	Phase 4	Modafinil;Placebo
6	MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study	Completed	NCT03226119	Phase 4
7	Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)	Unknown status	NCT00876772	Phase 2, Phase 3	Olanzapine
8	Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis	Unknown status	NCT00069186	Phase 3	Creatine Monohydrate
9	Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT02588677	Phase 2, Phase 3	Masitinib (4.5);Riluzole;Placebo;Masitinib (3.0)
10	A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00445172	Phase 2, Phase 3	E0302 (mecobalamin)
11	Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)	Completed	NCT00353665	Phase 2, Phase 3	Memantine (Ebixa);riluzole;Placebo
12	Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis	Completed	NCT01492686	Phase 3	MCI-186;Placebo;MCI-186 in open label phase
13	A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00444613	Phase 2, Phase 3	E0302 (mecobalamin);E0302 (mecobalamin);Placebo
14	Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis	Completed	NCT00706147	Phase 2, Phase 3	Arimoclomol;Placebo
15	Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00424463	Phase 3	MCI-186;Placebo of MCI-186
16	Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial	Completed	NCT00035815	Phase 3	Insulin like growth factor, type 1;Placebo
17	The Effect of GCSF in the Treatment of ALS Patients	Completed	NCT01825551	Phase 2, Phase 3	Granulocyte Colony Stimulating Factor;Placebo
18	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00330681	Phase 3	MCI-186;Placebo of MCI-186
19	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III	Completed	NCT00415519	Phase 3	MCI-186;Placebo of MCI-186
20	Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00868166	Phase 2, Phase 3	Olesoxime;Placebo Comparator
21	Phase 3 Study of Dexpramipexole in ALS	Completed	NCT01281189	Phase 3	Dexpramipexole;Placebo
22	Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT01933321	Phase 2, Phase 3
23	Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis	Completed	NCT00833820	Phase 2, Phase 3
24	Minocycline to Treat Amyotrophic Lateral Sclerosis	Completed	NCT00047723	Phase 3	minocycline
25	Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls	Completed	NCT01160263	Phase 3	SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
26	Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS	Completed	NCT00372879	Phase 3
27	Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis	Completed	NCT00136110	Phase 3	Sodium Valproate
28	Clinical Trial Ceftriaxone in Subjects With ALS	Completed	NCT00349622	Phase 3	ceftriaxone
29	Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)	Completed	NCT00125203	Phase 2, Phase 3	Botulinum toxin type B (Myobloc)
30	A Study for Patients Who Completed VITALITY-ALS (CY 4031)	Completed	NCT02936635	Phase 3	tirasemtiv
31	Safety Extension Study of TRO19622 in ALS	Completed	NCT01285583	Phase 2, Phase 3	TRO19622
32	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year	Completed	NCT02496767	Phase 3	tirasemtiv;Placebo tablets;Riluzole 50 MG
33	Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS	Completed	NCT00021697	Phase 3	AVP-923
34	Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS	Completed	NCT00573443	Phase 3	dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
35	Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement	Completed	NCT00386464	Phase 2, Phase 3
36	Escitalopram (Lexapro) for Depression MS or ALS	Completed	NCT00965497	Phase 3	escitalopram
37	Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease	Completed	NCT01776970	Phase 2, Phase 3	Cannabis Sativa extract Oromucosal spray
38	Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)	Completed	NCT01257828	Phase 3	riluzole;Placebo medication
39	Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects	Completed	NCT01994109	Phase 3	MYOBLOC
40	Arimoclomol in Amyotropic Lateral Sclerosis	Recruiting	NCT03491462	Phase 3	Arimoclomol;Placebo oral capsule
41	Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease	Recruiting	NCT03690791	Phase 3	CannTrust CBD Oil (capsule);Placebo (capsule)
42	Clinical Trial of Ultra-high Dose Methylcobalamin for ALS	Recruiting	NCT03548311	Phase 3	methylcobalamin;saline solution
43	Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients	Recruiting	NCT03280056	Phase 3
44	Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS	Recruiting	NCT03505021	Phase 3	Levosimendan;Placebo for levosimendan
45	Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)	Recruiting	NCT03347344	Phase 3	Riluzole;Placebo
46	Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis	Not yet recruiting	NCT03293069	Phase 2, Phase 3	Deferiprone;Placebo Oral Tablet
47	Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients	Not yet recruiting	NCT03127267	Phase 3	Masitinib (6.0);Riluzole;Placebo;Masitinib (4.5)
48	Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS	Not yet recruiting	NCT03800524	Phase 3	Tauroursodeoxycholic acid (TUDCA);Placebo
49	Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)	Terminated	NCT00818389	Phase 2, Phase 3	Lithium Carbonate;Riluzole;placebo
50	Phase 3 Extension Study of Dexpramipexole in ALS	Terminated	NCT01622088	Phase 3	Dexpramipexole

Search NIH Clinical Center for Lateral Sclerosis

Cochrane evidence based reviews: motor neuron disease

Sources

Genetic Tests for Lateral Sclerosis

Sources

Anatomical Context for Lateral Sclerosis

MalaCards organs/tissues related to Lateral Sclerosis:

⁴¹

Spinal Cord, Brain, Bone, Testes, Cortex, Bone Marrow, Skeletal Muscle

Sources

Publications for Lateral Sclerosis

Articles related to Lateral Sclerosis:

(show top 50) (show all 3674)

#	Title	Authors	Year
1	Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia. ( 30348461 )	Gkazi SA...Shaw CE	2019
2	Elucidating the End-of-Life Experience of Persons With Amyotrophic Lateral Sclerosis. ( 30422919 )	Long R...Amundson M	2019
3	Amyotrophic lateral sclerosis as a synaptopathy. ( 30530995 )	Fogarty MJ	2019
4	Amyotrophic lateral sclerosis: a complex syndrome that needs an integrated research approach. ( 30530996 )	Riancho J...L?pez de Muna?n A	2019
5	Safety of intrathecal injection of Wharton's jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy. ( 30531015 )	Barczewska M...Maksymowicz W	2019
6	Misdiagnosis: Hypoglossal palsy mimicking bulbar onset amyotrophic lateral sclerosis. ( 30555942 )	Goldstein ED...Eidelman BH	2019
7	Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. ( 30290270 )	Gordon D...Talbot K	2019
8	Mutation analysis of KIF5A in Chinese amyotrophic lateral sclerosis patients. ( 30301576 )	Zhang K...Zhang X	2019
9	Genetic activation of parkin rescues TAF15-induced neurotoxicity in a Drosophila model of amyotrophic lateral sclerosis. ( 30339961 )	Kim Y...Kim K	2019
10	UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. ( 30368160 )	Placek K...McMillan CT	2019
11	Defective daily temperature regulation in a mouse model of amyotrophic lateral sclerosis. ( 30031021 )	Braun MC...Schwartz WJ	2019
12	Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial. ( 30124008 )	Nabavi SM...Aghdami N	2019
13	Coexistence of Amyotrophic Lateral Sclerosis in the Proband of an X-Linked Charcot-Marie-Tooth Disease Type 1 Pedigree in China. ( 29629536 )	Feng S.Y....Zou Z.Y.	2018
14	Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. ( 29427042 )	Golomb B.A....Hoffman K.B.	2018
15	Imaging of glia activation in people with primary lateral sclerosis. ( 29159046 )	Paganoni S....Atassi N.	2018
16	Successful Management of Acquired Tracheomalacia of Patients With Amyotrophic Lateral Sclerosis: A Report of Three Cases. ( 29765893 )	Yang J.H....Shin Y.B.	2018
17	Whole blood transcriptome analysis in amyotrophic lateral sclerosis: A biomarker study. ( 29939990 )	van Rheenen W....van den Berg L.H.	2018
18	Therapeutic effects of percutaneous endoscopic gastrostomy on survival in patients with amyotrophic lateral sclerosis: A meta-analysis. ( 29408898 )	Cui F....Huang X.	2018
19	EFFECT OF WEDELOLACTONE AND GALLIC ACID ON QUINOLINIC ACID-INDUCED NEUROTOXICITY AND IMPAIRED MOTOR FUNCTION: SIGNIFICANCE TO SPORADIC AMYOTROPHIC LATERAL SCLEROSIS. ( 29981346 )	Maya S....Goli D.	2018
20	Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis. ( 29950436 )	Wolpaw J.R....Ruff R.L.	2018
21	Impact of expiratory strength training in amyotrophic lateral sclerosis: Results of a randomized sham controlled trial. ( 29981250 )	Plowman E.K....Gooch C.	2018
22	Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. ( 29254092 )	Ahmed R.M....Kiernan M.C.	2018
23	A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy. ( 29416499 )	Bond L....Mitchell C.S.	2018
24	Elevated Global DNA Methylation Is Not Exclusive to Amyotrophic Lateral Sclerosis and Is Also Observed in Spinocerebellar Ataxia Types 1 and 2. ( 29428949 )	Hamzeiy H....BaA9ak A.N.	2018
25	Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. ( 29941342 )	Salter M....Akoulitchev A.	2018
26	Crush injury to motor nerves in the G93A transgenic mouse model of amyotrophic lateral sclerosis promotes muscle reinnervation and survival of functionally intact nerve-muscle contacts. ( 29409912 )	Sharp P.S....Gordon T.	2018
27	Swallowing impairments in Amyotrophic Lateral Sclerosis and Myotonic Dystrophy type 1: Looking for the portrait of dysphagic patient in neuromuscular diseases. ( 29400682 )	Andrenelli E....Coccia M.	2018
28	Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. ( 29942091 )	Zhang Y.J....Petrucelli L.	2018
29	A blended psychosocial support program for partners of patients with amyotrophic lateral sclerosis and progressive muscular atrophy: protocol of a randomized controlled trial. ( 29716660 )	de Wit J....SchrAPder C.D.	2018
30	Molecular mechanisms underlying the impact of mutations in SOD1 on its conformational properties associated with amyotrophic lateral sclerosis as revealed with molecular modelling. ( 29431095 )	Alemasov N.A....Ivanisenko V.A.	2018
31	Amyotrophic Lateral Sclerosis after Receiving the Human Papilloma Virus Vaccine: A Case Report of a 15-year-old Girl. ( 29434138 )	Hikiami R....Takahashi R.	2018
32	Pseudobulbar Affect Correlates With Mood Symptoms in Parkinsonian Disorders but Not Amyotrophic Lateral Sclerosis. ( 29505320 )	Patel N....Jimenez-Shahed J.	2018
33	Radial diffusivity as an imaging biomarker for early diagnosis of non-demented amyotrophic lateral sclerosis. ( 29948064 )	Bao Y....Li Y.	2018
34	Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. ( 29128630 )	Yuan X....Shang H.	2018
35	No Benefit of Diaphragm Pacing in Upper Motor Neuron Dominant Forms of Amyotrophic Lateral Sclerosis. ( 29957023 )	MorAclot-Panzini C....Similowski T.	2018
36	Thoracoabdominal asynchrony and paradoxical motion in middle stage amyotrophic lateral sclerosis. ( 29969705 )	Sarmento A....Resqueti V.	2018
37	Association between TBK1 mutations and risk of amyotrophic lateral sclerosis/frontotemporal dementia spectrum: a meta-analysis. ( 29349657 )	Cui R....Zhou C.	2018
38	Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. ( 29417336 )	BrAouer S....Hermann A.	2018
39	Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum. ( 29868980 )	Agarwal S....Kiernan M.C.	2018
40	Sharing and Empathy in Digital Spaces: Qualitative Study of Online Health Forums for Breast Cancer and Motor Neuron Disease (Amyotrophic Lateral Sclerosis). ( 29903695 )	Hargreaves S....Ellis J.	2018
41	Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis. ( 29169899 )	Liu Z....Wang W.	2018
42	Motor and extra-motor gray matter integrity may underlie neurophysiologic parameters of motor function in amyotrophic lateral sclerosis: a combined voxel-based morphometry and transcranial stimulation study. ( 29417490 )	Christidi F....Karandreas N.	2018
43	Association between attention-deficit/hyperactivity disorder (ADHD) and amyotrophic lateral sclerosis (ALS). ( 29961556 )		2018
44	ERp57 is protective against mutant SOD1-induced cellular pathology in Amyotrophic Lateral Sclerosis. ( 29409023 )		2018
45	Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression. ( 29409450 )		2018
46	TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. ( 29954341 )		2018
47	Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. ( 29293261 )		2018
48	Amyotrophic Lateral Sclerosis Model. ( 29951816 )		2018
49	Transcriptomics in amyotrophic lateral sclerosis. ( 28930607 )		2018
50	Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. ( 29955173 )		2018

Sources

Genes for Lateral Sclerosis

Genes related to Lateral Sclerosis (0 elite genes):

(show all 33)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ALS2	ALS2, Alsin Rho Guanine Nucleotide Exchange Factor	Protein Coding	89.43	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Pathways & Interactions Transcripts Variants (show sections)
2	SOD1	Superoxide Dismutase 1	Protein Coding	78.71	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Pathways & Interactions Variants (show sections)
3	NEFH	Neurofilament Heavy	Protein Coding	67.95	GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions Functions Variants (show sections)
4	FUS	FUS RNA Binding Protein	Protein Coding	65.86	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
5	VCP	Valosin Containing Protein	Protein Coding	62.44	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants localization (show sections)
6	SIGMAR1	Sigma Non-Opioid Intracellular Receptor 1	Protein Coding	62.4	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants localization (show sections)
7	SETX	Senataxin	Protein Coding	61.32	GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
8	TARDBP	TAR DNA Binding Protein	Protein Coding	56.36	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants localization (show sections)
9	HNRNPA1	Heterogeneous Nuclear Ribonucleoprotein A1	Protein Coding	56.34	GeneCards inferred via : Disorders Publications Summaries Proteins Variants (show sections)
10	C9orf72	Chromosome 9 Open Reading Frame 72	Protein Coding	55.82	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
11	CHCHD10	Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 10	Protein Coding	47.85	GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
12	PRPH	Peripherin	Protein Coding	45.9	GeneCards inferred via : Publications Summaries Pathways & Interactions Variants (show sections)
13	TRPM7	Transient Receptor Potential Cation Channel Subfamily M Member 7	Protein Coding	45.27	GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
14	RNF19A	Ring Finger Protein 19A, RBR E3 Ubiquitin Protein Ligase	Protein Coding	45.17	GeneCards inferred via : Publications Summaries Proteins localization (show sections)
15	VAPB	VAMP Associated Protein B And C	Protein Coding	43.85	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
16	DCTN1	Dynactin Subunit 1	Protein Coding	43.22	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
17	FIG4	FIG4 Phosphoinositide 5-Phosphatase	Protein Coding	43.18	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
18	UBQLN2	Ubiquilin 2	Protein Coding	42.74	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
19	ANG	Angiogenin	Protein Coding	41.97	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
20	ALS2CR12	Amyotrophic Lateral Sclerosis 2 Chromosome Region 12	Protein Coding	36.63	GeneCards inferred via : Publications Gene name Proteins Transcripts (show sections)
21	ATXN2	Ataxin 2	Protein Coding	30.91	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries (show sections)
22	GRIA2	Glutamate Ionotropic Receptor AMPA Type Subunit 2	Protein Coding	30.06	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries Pathways & Interactions (show sections)
23	SQSTM1	Sequestosome 1	Protein Coding	28.99	GeneCards inferred via : Disorders Publications Variants (show sections)
24	OPTN	Optineurin	Protein Coding	28.86	GeneCards inferred via : Disorders Publications Variants (show sections)
25	TBK1	TANK Binding Kinase 1	Protein Coding	28.41	GeneCards inferred via : Disorders Publications Variants (show sections)
26	MATR3	Matrin 3	Protein Coding	27.67	GeneCards inferred via : Disorders Publications Variants (show sections)
27	PFN1	Profilin 1	Protein Coding	27.26	GeneCards inferred via : Disorders Publications Variants (show sections)
28	LOC109504728	Chromosome 9 Open Reading Frame 72 Repeat Instability Region	Uncategorized	27.1	GeneCards inferred via : Publications Gene name Summaries (show sections)
29	ANXA11	Annexin A11	Protein Coding	26.92	GeneCards inferred via : Disorders Publications Variants (show sections)
30	TUBA4A	Tubulin Alpha 4a	Protein Coding	26.84	GeneCards inferred via : Disorders Publications Variants (show sections)
31	KIF5A	Kinesin Family Member 5A	Protein Coding	26.64	GeneCards inferred via : Disorders Publications Variants (show sections)
32	SPG11	SPG11, Spatacsin Vesicle Trafficking Associated	Protein Coding	26.64	GeneCards inferred via : Disorders Publications Variants (show sections)
33	MPP4	Membrane Palmitoylated Protein 4	Protein Coding	26.56	GeneCards inferred via : Publications Gene name Variants (show sections)

Sources

Variations for Lateral Sclerosis

Sources

Expression for Lateral Sclerosis

Search GEO for disease gene expression data for Lateral Sclerosis.

Sources

Pathways for Lateral Sclerosis

Pathways related to Lateral Sclerosis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Neuroscience ⁴	11.89	DCTN1 NEFH SIGMAR1 SOD1 TARDBP
2	Cytoskeleton remodeling Neurofilaments ²² Show member pathways Cytoskeleton remodeling Keratin filaments ²²	11.37	DCTN1 NEFH PRPH
3	Amyotrophic lateral sclerosis (ALS) ¹ ³⁷ Show member pathways Pathogenesis of ALS ⁶⁴	10.98	ALS2 NEFH PRPH SOD1

Sources

GO Terms for Lateral Sclerosis

Cellular components related to Lateral Sclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasmic vesicle	GO:0031410	9.77	ANG C9orf72 SIGMAR1 SOD1 UBQLN2
2	neuronal cell body	GO:0043025	9.55	ALS2 ANG DCTN1 FUS SOD1
3	lipid droplet	GO:0005811	9.43	FIG4 SIGMAR1 VCP
4	axon	GO:0030424	9.35	ALS2 C9orf72 DCTN1 NEFH SETX
5	growth cone	GO:0030426	9.02	ALS2 ANG C9orf72 SETX SIGMAR1
6	cytoplasm	GO:0005737	10.17	ALS2 ALS2CR12 C9orf72 DCTN1 FUS HNRNPA1

Biological processes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	locomotory behavior	GO:0007626	9.33	ALS2 FIG4 SOD1
2	regulation of autophagosome assembly	GO:2000785	8.96	C9orf72 UBQLN2
3	neurofilament cytoskeleton organization	GO:0060052	8.62	NEFH SOD1

Molecular functions related to Lateral Sclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.53	ALS2 ALS2CR12 ANG C9orf72 CHCHD10 DCTN1
2	dynein complex binding	GO:0070840	8.96	DCTN1 NEFH

Sources

Sources for Lateral Sclerosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia